A novel model for predicting prognosis in pancreatic cancer patients: a retrospective study

Multivariate regression analysis showed that neutrophils (hazard ratio (HR) = 1.416, 95% confidence interval (CI) = 1.037-1.932, <i>P</i> = 0.028), lymphocytes (HR = 0.625, 95% CI = 0.462-0.846, <i>P</i> = 0.002), Carcinoembryonic Antigen (CEA) (HR = 1.820, 95% CI = 1.315-2.518, <i>P</i> < 0.001), CA125 (HR = 1.392, 95% CI = 1.001-1.936, <i>P</i> = 0.049), TNM stage (I vs. III: HR = 3.052, 95% CI = 1.900-4.905, <i>P</i> < 0.001; I vs. IV: HR = 4.815, 95% CI = 2.504-9.258, <i>P</i> < 0.001) and Neutrophil-to-Lymphocyte Ratio (NLR) (HR = 1.748, 95% CI = 1.210-2.525, <i>P</i> = 0.003), Lymphocyte-to-Monocyte Ratio (LMR) (HR = 0.597, 95% CI = 0.430-0.829, <i>P</i> = 0.002), Neutrophil-to-Macrophage Ratio (NMR) (HR = 2.065, 95% CI = 1.331-3.206, <i>P</i> = 0.001), and Systemic Immune-Inflammation Index (SII) (HR = 1.751, 95% CI = 1.244-2.466, <i>P</i> = 0.001) were independent risk factors for OS. We have developed a new model incorporating gender, age, treatment, TNM stage, pathological grade, CEA, CA125, and NLR. The model demonstrates good predictive performance, with a C-index of 0.73.